Skip to content
Open access

Role of SLC25A39 in IFNγ-induced MHC-I Expression in a Pancreatic Cancer Cell Model

2026 · American Journal of Student Research · 0 citations

Abstract

Immunotherapy has revolutionized cancer treatment. One of the key mediators of tumor-immune interactions is the major histocompatibility complex (MHC) class I (MHC-I), a protein expressed on the surface of cancer cells to present tumor-derived antigens to CD8+ T cells, and loss or downregulation of MHC-I contributes to resistance to immunotherapy. Interferon-gamma (IFNγ) is a potent inducer of MHC-I expression through activation of JAK-STAT signaling, but molecular mechanisms of this response remain insufficiently understood. Recent studies have identified SLC25A39 as a mitochondrial glutathione transporter essential for mitochondrial redox regulation. Because mitochondrial pathways influence immune function, it is hypothesized that SLC25A39 contributes to IFNγ-mediated regulation of MHC-I expression. To test this hypothesis, the MT-3 mouse pancreatic cancer cell line with CRISPRmediated editing of the Slc25a39 gene was used, with a predicted loss-of-function frameshift mutation of SLC25A39 verified by Sanger sequencing. Wild-type and Slc25a39-edited MT-3 cells were stimulated with increasing concentrations of IFNγ, and MHC-I expression was analyzed by flow cytometry. IFNγ treatment induced a dose-dependent induction of MHC-I on MT-3 cells, with a modest increase observed in Slc25a39-edited cells compared with wild-type controls. These findings establish MT-3 cells as a robust cell model system to investigate IFNγ-induced MHC-I expression and suggest a potential effect of mitochondrial pathways in tumor cell MHC-I regulation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.